Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Polverino, C. Cilloniz, A. Gabarrus, S. Ewig, T. Welte, O. Rajas, A. Capelastegui, J. Almirall, A. Torres (Barcelona, Madrid, Maresme, Spain; , ; Hanover, Germany). Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study. Eur Respir J 2012; 40: Suppl. 56, 4376

Member's Comments

No comment yet.

Related content which might interest you: A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003 Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007 Comparative prospective cohort study of the efficacy and safety according to dose of Ceftriaxone in community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004 Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 714s Year: 2004 Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021 Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Comparative efficacy and safety of five-day moxifloxacin and seven-day ceftriaxone treatment of AECB: results of the SMART study Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea Source: Eur Respir J, 51 (3) 1702467; 10.1183/13993003.02467-2017 Year: 2018 Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Randomized, controlled trial of efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006 Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018 Year: 2018